Pinkerton Wealth LLC Invests $934,000 in Alnylam Pharmaceuticals, Inc. $ALNY

Pinkerton Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,049 shares of the biopharmaceutical company’s stock, valued at approximately $934,000.

Several other hedge funds have also recently made changes to their positions in the company. Fieldview Capital Management LLC purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth about $5,772,000. WINTON GROUP Ltd raised its position in shares of Alnylam Pharmaceuticals by 92.5% in the third quarter. WINTON GROUP Ltd now owns 6,800 shares of the biopharmaceutical company’s stock valued at $3,101,000 after purchasing an additional 3,267 shares during the period. Schroder Investment Management Group lifted its stake in shares of Alnylam Pharmaceuticals by 26.1% during the 3rd quarter. Schroder Investment Management Group now owns 10,818 shares of the biopharmaceutical company’s stock valued at $4,841,000 after buying an additional 2,238 shares in the last quarter. Jefferies Financial Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 98.3% in the 3rd quarter. Jefferies Financial Group Inc. now owns 16,542 shares of the biopharmaceutical company’s stock worth $7,543,000 after buying an additional 8,200 shares during the period. Finally, B. Metzler seel. Sohn & Co. AG raised its holdings in Alnylam Pharmaceuticals by 21.0% during the 3rd quarter. B. Metzler seel. Sohn & Co. AG now owns 3,913 shares of the biopharmaceutical company’s stock valued at $1,784,000 after acquiring an additional 680 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Up 0.9%

Shares of ALNY stock opened at $323.53 on Tuesday. The business has a 50-day moving average price of $350.74 and a two-hundred day moving average price of $413.17. The firm has a market cap of $42.91 billion, a P/E ratio of 189.20 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same period last year, the business posted ($0.65) earnings per share. The company’s revenue was up 84.9% compared to the same quarter last year. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

ALNY has been the subject of several recent research reports. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Leerink Partners lowered their price target on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. Needham & Company LLC decreased their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Finally, HC Wainwright restated a “buy” rating and set a $510.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $477.96.

Insider Buying and Selling

In other news, EVP Jeffrey V. Poulton sold 2,780 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the completion of the sale, the executive vice president owned 57,465 shares of the company’s stock, valued at approximately $20,852,324.55. This represents a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the transaction, the executive vice president directly owned 21,264 shares in the company, valued at approximately $7,874,697.12. The trade was a 9.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 53,923 shares of company stock worth $18,072,087 in the last ninety days. Corporate insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.